Skip to main content

Table 2 Response and Survival for all patients

From: Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

 

Cohort 1 (n = 33)

Cohort 2 (n = 18)

P

Total (n = 51)

Outcome

No.

%

No.

%

 

No.

%

CR+PR No.

16

48.5

6

33.3

 

22

43.1

SD No.

11

33.3

7

38.9

 

18

35.3

PD No.

6

18.2

5

27.8

 

11

21.6

Response rate

16

48.5

6

33.3

0.668

22

43.1

Median PFS (days)

120

116

 

120

95% CI

77.2-162. 8

0-267.1

0.377

79.7-160.3

Median OS (days)

252

265

 

265

95% CI

157. 5-346.5

107.0-423.0

0.354

181.0-349.0

  1. NOTE: PFS, progression-free survival; OS, overall survival; 95% CI: 95% confidence interval